Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Patrick M FordeJamie E ChaftKellie N SmithValsamo AnagnostouTricia R CottrellMatthew D HellmannMarianna ZahurakStephen C YangDavid R JonesStephen BroderickRichard J BattafaranoMoises J VelezNatasha RekhtmanZachary OlahJarushka NaidooKristen A MarroneFranco VerdeHaidan GuoJiajia ZhangJustina X CaushiHok Yee ChanJohn-William SidhomRobert B ScharpfJames WhiteEdward GabrielsonHao WangGary L RosnerValerie RuschJedd D WolchokTaha MerghoubJanis M TaubeVictor E VelculescuSuzanne L TopalianJulie R BrahmerDrew M PardollPublished in: The New England journal of medicine (2018)
Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute-Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621 .).
Keyphrases